GGrantIndex
Sort

39,280 grants matching leukemia

Immunology And Pathology Of Murine Leukemia Virus Infections

$2,036,332
Kim Hasenkrug · Niaid Extramural Activities · Z01 · FY2007 · AI

Immunogenetics of Graft-Versus-Host Disease

$2,035,982
Effie W Petersdorf · Fred Hutchinson Cancer Research Center · P01 · FY2014 · CA

Specialized Program Of Research Excellence (SPORE) in Leukemia.

$2,035,962
Daniel C Link · Washington University · P50 · FY2021 · CA

University of New Mexico Cancer Center Support

$2,035,899
Cheryl L Willman · University Of New Mexico Health Scis Ctr · P30 · FY2010 · CA

Hematopoietic Stem Cells for Transplantation

$2,035,680
Curt I Civin · Johns Hopkins University · P01 · FY2008 · CA

Mechanisms of GVHD

$2,035,506
Joseph H Antin · Dana-Farber Cancer Inst · P01 · FY2006 · HL

Development of New Antitumor Agents

$2,034,948
Southern Research Institute · P01 · FY2001 · CA

Mechanisms of GVHD

$2,034,180
Dana-Farber Cancer Institute · P01 · FY2005 · HL

Immunologic Approaches to Ovarian Cancer

$2,033,832
Paul J Sabbatini · Sloan-Kettering Inst Can Research · P01 · FY2018 · CA

Immunologic Approaches to Ovarian Cancer

$2,033,832
Paul J Sabbatini · Sloan-Kettering Inst Can Research · P01 · FY2017 · CA

Immunologic Approaches to Ovarian Cancer

$2,033,832
David R Spriggs · Sloan-Kettering Inst Can Research · P01 · FY2016 · CA

IL-2 Family Cytokines and Receptors-- Mechanisms of Regulation & Action

$2,032,463
Warren J Leonard · National Heart, Lung, And Blood Institute · ZIA · FY2019 · HL

Molecular Profiling of Clinical Specimens

$2,032,400
Daniel Edelman · Division Of Basic Sciences - Nci · ZIC · FY2014 · CA

Loss of miR-29s as predictor of response to demethylating agents

$2,031,555
Carlo M Croce · Ohio State University · RC2 · FY2009 · CA

Developmental Therapeutics Program

$2,029,064
James V Degregori · University Of Colorado Denver · P30 · FY2025 · CA

THE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCE

$2,029,001
Mark A Watson · Washington University · U24 · FY2017 · CA

Molecular Pathways to Thynmic Lymphoma and Leukemia

$2,028,518
A Thomas Look · Dana-Farber Cancer Inst · P01 · FY2011 · CA

Therapy of Lymphoma/Leukemia with Monoclonal Antibodies

$2,026,942
Oliver W. Press · Fred Hutchinson Cancer Research Center · P01 · FY2009 · CA

Loss of miR-29s as predictor of response to demethylating agents

$2,026,079
Carlo M Croce · Ohio State University · RC2 · FY2010 · CA

Mechanisms of GVHD

$2,025,615
Joseph H Antin · Dana-Farber Cancer Inst · P01 · FY2007 · HL

Hematopoietic Chimerism after Stem Cell Allografts

$2,023,730
Rainer F. Storb · Fred Hutchinson Cancer Research Center · P01 · FY2017 · CA

Hematopoietic Chimerism after Stem Cell Allografts

$2,023,730
Rainer F. Storb · Fred Hutchinson Cancer Research Center · P01 · FY2016 · CA

Molecular Pathways to Thynmic Lymphoma and Leukemia

$2,022,365
A Thomas Look · Dana-Farber Cancer Inst · P01 · FY2012 · CA

Targeted Sphingolipid Metabolism for Treatment of AML

$2,019,502
Thomas P Loughran · University Of Virginia · P01 · FY2017 · CA

Targeted Sphingolipid Metabolism for Treatment of AML

$2,019,502
Thomas P Loughran · University Of Virginia · P01 · FY2016 · CA